Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This phase II trial evaluates the diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing treatment response in patients undergoing transarterial chemoembolization (TACE) for liver tumors. TACE is a hepatic artery embolization technique involving the injection of a blocking agent and a chemotherapy agent to treat liver cancers. Currently, contrast enhanced magnetic resonance imaging or computed tomography are used to assess disease response 1-2 months after TACE treatment, but ultrasound may be a less expensive, earlier alternative. CEUS is an imaging procedure that uses high-frequency sound waves to generate images of the body after administering Lumason, an imaging agent used to enhance visualization of blood flow on ultrasounds. CEUS is able to be performed during the TACE procedure, making it possible to evaluate treatment response earlier than standard techniques. CEUS may be an effective method to evaluate treatment response more accurately and much earlier than current standard evaluation methods.
Sponsor: john eisenbrey
You may qualify if…
- ✓ Scheduled for TACE therapy of a liver tumor
- ✓ Be at least 18 years of age
- ✓ Be medically stable
- ✓ If a female of child-bearing age, must have a negative pregnancy test
- ✓ Have signed informed consent to participate in the study
You may not qualify if…
- ✕ Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable
- ✕ Patients with known sensitivities to the components of lumason
Where it's recruiting
Philadelphia
Source: ClinicalTrials.gov · NCT06261814 · last updated 2026-02-17